Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy-Reference-Cited by-同舟云学术

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy

Published:2008-12 Issue:12 Volume:19 Page:2089-2090
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Akiyama Y.,Fujita K.,Nagashima F.,Yamamoto W.,Endo H.,Sunakawa Y.,Yamashita K.,Ishida H.,Mizuno K.,Araki K.,Ichikawa W.,Miya T.,Narabayashi M.,Kawara K.,Sugiyama M.,Hirose T.,Ando Y.,Sasaki Y.

Funder

Grant-in-Aid for Cancer Research

Health and Labour Sciences Research Grant from the Ministry of Health

Labour and Welfare of Japan

Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science

Japan Research Foundation for Clinical Pharmacology

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/12/2089/401163/mdn645.pdf

Reference5 articles.

1. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis;Ando;Cancer Res,2000

2. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan;Innocenti;J Clin Oncol,2004

3. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters;Hoskins;J Natl Cancer Inst,2007

4. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28;Minami;Pharmacogenet Genomics,2007

5. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer;Araki;Cancer Sci,2006

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer;Cancer Medicine;2024-09

2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer;ESMO Open;2023-06

3. Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan;European Journal of Human Genetics;2022-11-28

4. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer;International Journal of Clinical Oncology;2022-05-30

5. Drug‐Drug Interactions and Disease Status Are Associated With Irinotecan‐Induced Hepatotoxicity: A Cross‐Sectional Study in Shanghai;The Journal of Clinical Pharmacology;2022-05-06